Case Report
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Oct 24, 2024; 15(10): 1351-1358
Published online Oct 24, 2024. doi: 10.5306/wjco.v15.i10.1351
Disitamab vedotin combined with apatinib in gastric cancer: A case report and review of literature
Xiao-Qian Li, Jing Yang, Bo Liu, Shu-Mei Han
Xiao-Qian Li, Jing Yang, Bo Liu, Shu-Mei Han, Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 510000, Shandong Province, China
Author contributions: Li XQ, Han SM written the draft of the manuscript; Liu B polished the manuscript and Yang J prepared figures; all authors commented on the previous versions of the manuscript; all authors read and approved the final manuscript.
Informed consent statement: The patient had sighed the Informed consent form.
Conflict-of-interest statement: No potential conflict of interest was reported by the author(s).
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shu-Mei Han, PhD, Associate Chief Physician, Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, No. 440 Jiyan Highway, Huaiyin District, Jinan 510000, Shandong Province, China. 15553115908@163.com
Received: April 15, 2024
Revised: August 18, 2024
Accepted: August 29, 2024
Published online: October 24, 2024
Processing time: 166 Days and 17.2 Hours
Core Tip

Core Tip: Apatinib exhibits synergistic effect with pan-HER inhibitor and reverses acquired resistance in human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) via stem cell factor/c-kit signaling and its downstream pathways. The patient treated with HER2-targeted therapy (disitamab vedotin, RC48) and small molecule antiangiogenesis targeted therapy with apatinib experiencing excellent survival, which provide related data for posterior line treatment of advanced GC.